AriBio Shares Experience Independently Conducting Global Phase 3 Alzheimer's Trial

1,535 participants across 240 sites in 13 countries
More than 150 billion won secured in upfront payments from licensing agreements
POLARIS-AD topline results to be presented at CTAD on November 16

AriBio shared its experience independently conducting a global Phase 3 trial of AR1001, an oral candidate treatment for Alzheimer's disease.

AriBio said on October 16 that it had presented the operational framework and fundraising experience for POLARIS-AD, a global Phase 3 trial, at the KIC 2026 International Conference held at the Lotte Hotel in Seoul on October 15.

Fred Kim, head of AriBio's U.S. branch, speaks at KIC 2026, held at Lotte Hotel in Jung-gu, Seoul, on the 15th. AriBio

POLARIS-AD enrolled 1,535 patients with early Alzheimer's disease at 240 sites in 13 countries. Participants received either 30 mg of AR1001 or a placebo for 52 weeks, and 87.8% (1,348 participants) completed treatment.

AriBio led the trial design and regulatory strategy through its U.S. clinical operations team, managing the trial with regional contract research organizations (CROs) and its own monitoring staff. Trial costs were covered using support from AriBio Holdings and more than 150 billion won in upfront payments secured through exclusive global regional licensing agreements.

Topline results from POLARIS-AD are scheduled to be presented for the first time on November 16 at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, United States.

This content was produced with the assistance of AI translation services.